| Literature DB >> 27759111 |
Zongshi Qin1,2, Jiani Wu1, Jinhui Tian3, Jing Zhou1, Yali Liu3,4, Zhishun Liu1.
Abstract
Alpha-blockers and antibiotics are most commonly used to treat chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in clinical practice. Currently, increasing evidence also suggests acupuncture as an effective strategy. This network meta-analysis intended to assess the comparative efficacy and safety of acupuncture, alpha-blockers and antibiotics for CP/CPPS. Twelve trials involving 1203 participants were included. Based on decreases in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score, a network meta-analysis indicated that electro-acupuncture (standard mean difference [SMD]: 4.29; 95% credible interval [CrI], 1.96-6.65), acupuncture (SMD: 3.69; 95% CrI, 0.27-7.17), alpha-blockers (SMD: 1.85; 95% CrI, 1.07-2.64), antibiotics (SMD: 2.66; 95% CrI, 1.57-3.76), and dual therapy (SMD: 3.20; 95% CrI, 1.95-4.42) are superior to placebo in decreasing this score. Additionally, electro-acupuncture (SMD: 2.44; 95% CrI, 0.08-4.83) and dual therapy (SMD: 1.35; 95% CrI, 0.07-2.62) were more effective than alpha-blockers in decreasing the total NIH-CPSI total score. Other network meta-analyses did not show significant differences between interventions other placebo. The incidence of adverse events of acupuncture was relatively rare (5.4%) compared with placebo (17.1%), alpha-blockers (24.9%), antibiotics (31%) and dual therapy (48.6%). Overall, rank tests and safety analyses indicate that electro-acupuncture/acupuncture may be recommended for the treatment of CP/CPPS.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27759111 PMCID: PMC5069632 DOI: 10.1038/srep35737
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1PRISMA flow chart
Characteristics of Included Studies.
| Study ID | Location | Sample size and intervention | Age | Duration | Outcome | Adverse events |
|---|---|---|---|---|---|---|
| Lee | Malaysia | 44 acupuncture | 40.9 ± 11.0 | 10 weeks | NIH-CPSI | 8 |
| 45 sham acupuncture | 42.8 ± 9.4 | 5 | ||||
| Lee | Korea | 12 electro-acupuncture | 39.8 ± 5.8 | 6 weeks | NIH-CPSI | 0 |
| 12 sham acupuncture | 36.4 ± 5.8 | 1 | ||||
| Sahin | Turkey | 45 acupuncture | 32.1 ± 7.2 | 6 weeks | NIH-CPSI | 0 |
| 46 sham acupuncture | 32.8 ± 7.0 | |||||
| Kucuk | Turkey | 26 electro-acupuncture | 33.3 (17–50) | 7 weeks | NIH-CPSI | 0 |
| 28 levofloxacin + ibuprofen | 6 weeks | |||||
| Cheah | Malaysia | 43 placebo | 35 (20–50) | 14 weeks | NIH-CPSI | 11 |
| 43 terazocin | 36 (24–49) | 21 | ||||
| Nickel | Canada | 45 placebo | 56.2 (36–78) | 6 weeks | NIH-CPSI | 5 |
| 35 levofloxacin | 56.0 (39–77) | 8 | ||||
| Alexander | Canada/USA | 45 placebo | 42.6 ± 12.0 | 6 weeks | NIH-CPSI | 20 |
| 45 tamsulosin | 45.3 ± 9.7 | 20 | ||||
| 42 ciprofloxacin | 45.9 ± 11.7 | 19 | ||||
| 42 tamsulosin + ciprofloxacin | 44.5 ± 11.4 | 17 | ||||
| Tugcu | Turkey | 29 placebo | 29.1 ± 5.2 | 24 weeks | NIH-CPSI | 6 |
| 29 doxazosin | 12 | |||||
| 28 doxazosin + ibuprofen | 17 | |||||
| Nickel | USA/Malaysia | 138 placebo | 40.1 ± 12.3 | 12 weeks | NIH-CPSI | 7 |
| 134 alfuzosin | 40.1 ± 11.4 | 3 | ||||
| Zhou | China | 24 placebo | NR | 12 weeks | NIH-CPSI | NR |
| 24 tetracycline | ||||||
| Nickel | Canada | 54 placebo | 49.0 ± 11.6 | 12 weeks | NIH-CPSI | 7 |
| 52 silodosin | 49.2 ± 13.3 | 18 | ||||
| Chen | China | 47 placebo | 33.3 ± 7.2 | 24 weeks | NIH-CPSI | 2 |
| 46 tamsulosin | 35.3 ± 6.8 | 13 |
Summary of the included studies.
NIH-CPSI: National Institutes of Health Chronic Prostatitis Symptom Index; NR: not reported.
*Age is provided as the mean ± standard deviation or mean (range).
Figure 2Network plot.
Risk of Bias Assessment.
| Study ID | Sequence generation | Allocation concealment | Blinding | Incomplete outcome | Selective outcome report | Other source of bias |
|---|---|---|---|---|---|---|
| Lee | L | U | L | L | L | L |
| Lee | L | U | L | L | L | H |
| Sahin | L | U | L | L | L | L |
| Kucuk | L | U | H | H | L | L |
| Cheah | L | U | L | L | L | L |
| Nickel | L | L | L | L | L | L |
| Alexander | L | L | L | L | L | L |
| Tugcu | U | U | L | L | L | L |
| Nickel | L | L | L | L | L | L |
| Zhou | U | U | U | U | L | H |
| Nickel | L | U | L | L | L | L |
| Chen | L | U | L | L | L | L |
L: low risk of bias; H: high risk of bias; U: unclear.
Risk of bias assessment.
Results of National Institutes of Health Chronic Prostatitis Symptom Index Total Score.
| 2.71 (−0.42, 5.88) | ||||||
| 0.81 (−0.44, 2.05) | 1.84 (−1.61, 5.31) | 0.86 (−2.29, 4.04) | ||||
| 0.26 (−0.16, 0.68) | 1.03 (−2.49, 4.61) | 1.63 (−0.86, 4.13) | 0.05 (−3.16, 3.29) | 0.54 (−0.95, 2.04) | ||
| NA | NA | NA | 0.60 (−1.92, 3.09) | −0.98 (−2.38, 0.42) | −0.49 (−3.71, 2.72) | |
| NA | NA | NA | NA | −1.58 (−3.67, 0.51) | −1.09 (−3.09, 0.90) | |
| NA | NA | NA | −0.49 (−2.42, 3.37) | |||
| 4.95 (−4.26, 13.45) | 0.05 (−0.27, 0.37) | −0.31 (−0.73, 0.10) | NA | NA |
PLA: placebo; ALP: alpha-blocker; ANT: antibiotic; ACU: acupuncture; EAC: electro-acupuncture; SAC: sham acupuncture; DT: dual therapy. NA: not available.
Results of direct and indirect comparisons in the total National Institutes of Health Chronic Prostatitis Symptom Index score.
Figure 3SUCRA for NIH-CPSI total score.
Results of National Institutes of Health Chronic Prostatitis Symptom Index Pain Score.
| 0.69 (−0.08, 1.47) | 0.61 (−2.79, 3.40) | −0.08 (−3.16, 3.02) | ||||
| 0.78 (−0.46, 2.00) | −0.08 (−3.49, 3.32) | 1.61 (−0.74, 3.95) | −0.77 (−3.90, 2.34) | 0.77 (−0.49, 2.03) | ||
| 1.28 (−0.29, 2.85) | 0.17 −0.25, 0.59 | −0.86 (−4.36, 2.63) | 0.83 (−1.63, 3.28) | −1.55 (−4.77, 1.64) | −0.01 (−1.48, 1.46) | |
| NA | NA | NA | ACU | 1.69 (−0.78, 4.15) | −0.69 (−2.07, 0.68) | 0.85 (−2.29, 4.03) |
| NA | NA | NA | NA | −0.83 (−2.81, 1.14) | ||
| NA | NA | NA | −0.69 (−1.63, 0.25) | 1.55 (−1.30, 4.39) | ||
| 2.28 (−2.27, 6.67) | −0.02 (−0.35, 0.30) | −0.29 (−0.71, 0.14) | NA | NA |
PLA: placebo; ALP: alpha-blocker; ANT: antibiotic; ACU: acupuncture; EAC: electro-acupuncture; SAC: sham acupuncture; DT: dual therapy. NA: not available.
Results of direct and indirect comparisons in National Institutes of Health Chronic Prostatitis Symptom Index pain score.
Figure 4SUCRA for NIH-CPSI pain score.
Results of National Institutes of Health Chronic Prostatitis Symptom Index Voiding Score.
| 2.29 (−1.03, 5.59) | 2.18 (−0.11, 4.46) | 1.45 (−1.60, 4.47) | ||||
| 1.38 (−1.94, 4.70) | 1.27 (−1.02, 3.56) | 0.54 (−2.52, 3.57) | 0.77 (−0.46, 2.01) | |||
| 0.19 −0.23, 0.62 | 0.04 (−3.38, 3.44) | −0.07 (−2.49, 2.34) | −0.80 (−3.94, 2.32) | −0.57 (−2.01, 0.89) | ||
| NA | NA | NA | −0.11 (−2.54, 2.31) | −0.84 (−2.19, 0.52) | −0.61 (−3.70, 2.49) | |
| NA | NA | NA | NA | −0.73 (−2.74, 1.28) | −0.50 (−2.44, 1.45) | |
| NA | NA | NA | −0.73 (−1.56, 0.10) | 0.23 (−2.43, 3.03) | ||
| 1.66 (−1.02, 4.34) | 0.25 (−0.10, 0.59) | −0.1 (−0.53, 0.33) | NA | −0.49 (−1.03, 0.05) | NA |
PLA: placebo; ALP: alpha-blocker; ANT: antibiotic; ACU: acupuncture; EAC: electro-acupuncture; SAC: sham acupuncture; DT: dual therapy. NA: not available.
Results of direct and indirect comparisons in National Institutes of Health Chronic Prostatitis Symptom Index voiding score.
Figure 5SUCRA for NIH-CPSI voiding score.
Results of National Institutes of Health Chronic Prostatitis Symptom Index Quality of Life Score.
| 2.21 (−1.04, 5.47) | 1.70 (−0.51, 3.93) | 1.11 (−1.85, 4.08) | ||||
| 1.36 (−1.90, 4.62) | 0.86 (−1.38, 3.09) | 0.26 (−2.71, 3.24) | 0.40 (−0.80, 1.58) | |||
| 1.00 (−0.17, 2.16) | 0.27 −0.15, 0.69 | 1.00 (−2.34, 4.35) | 0.48 (−1.86, 2.84) | −0.11 (−3.18, 2.96) | 0.03 (−1.38, 1.42) | |
| NA | NA | NA | −0.50 (−2.88, 1.87) | −1.10 (−2.41, 0.21) | −1.00 (−4.00, 2.07) | |
| NA | NA | NA | NA | −0.60 (−2.57, 1.37) | −0.50 (−2.34, 1.43) | |
| NA | NA | NA | −0.59 (−1.41, 0.23) | 0.14 (−2.59, 2.88) | ||
| 1.77 (−1.63, 5.17) | −0.18 (−0.58, 0.23) | NA | NA | −0.46 (−1.00, 0.08) | NA |
PLA: placebo; ALP: alpha-blocker; ANT: antibiotic; ACU: acupuncture; EAC: electro-acupuncture; SAC: sham acupuncture; DT: dual therapy. NA: not available.
Results of direct and indirect comparisons in National Institutes of Health Chronic Prostatitis Symptom Index quality of life score.
Figure 6SUCRA for NIH-CPSI QoL score.